Shire Pharmaceuticals Group PLC Third Quarter 2004 Results Date Notification - 4th November
BASINGSTOKE, England, October 18 /PRNewswire-FirstCall/ -- Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) will announce third quarter 2004 earnings on Thursday, 4 November 2004.
Results announcement time: 12:00 GMT / 07:00 ET Conference call time: 14:00 GMT / 09:00 ET Live conference call:
Matthew Emmens, Chief Executive Officer, Angus Russell, Chief Financial Officer and Greg Flexter, EVP and General Manager, North America will host the live analyst and investor conference call at 14:00 GMT/09:00 ET. The details of the conference call are as follows:
UK dial in +44-(0)20-7984-7576 US / Canada dial in +1-718-354-1157 Password Shire Pharmaceuticals Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through http://www.shire.com/ in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for 1 week. Details are as follows:
UK dial in +44-(0)20-7984-7578 Pin code 395273 US dial in +1-718-354-1112 Pin code 395273 Webcast Replay http://www.shire.com/, in the investor relations section
If you have any problems accessing this, please contact: Souheil Salah on: +44-(0)1256-894160
Notes to Editors Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company's website: http://www.shire.com/.
Shire Pharmaceuticals Group PlcCONTACT: For further information please contact: Souheil Salah, InvestorRelations, +44-(0)1256-894-160